Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally
advanced esophageal cancer. However, as high as more than 40% of patients with esophageal
cancer experienced locoregional recurrence after definitive CRT. Immune checkpoint inhibitors
targeting PD-1/PD-L1 and/or CTLA-4 have shown substantial clinical benefits in advanced
esophageal cancer. Recently, the combination of immunotherapy with CRT has emerged as a
promising strategy to improve clinical outcomes in esophageal cancer. The aim of this study
was to evaluate the efficacy and safety of cadonilimab (a bispecific PD-1/CTLA-4 antibody)
combined with induction chemotherapy followed by definitive radiotherapy in patients with
locally advanced esophageal squamous cell carcinoma.